Statistics for Patient Reported Outcomes (PRO) and Tolerability of Capivasertib (Capi) plus Abiraterone (Abi) versus Placebo (Pbo) plus Abi in Patients (Pts) with PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): CAPItello-281
Total visits
| views | |
|---|---|
| Patient Reported Outcomes (PRO) and Tolerability of Capivasertib (Capi) plus Abiraterone (Abi) versus Placebo (Pbo) plus Abi in Patients (Pts) with PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): CAPItello-281 | 0 |
Total visits per month
| views | |
|---|---|
| November 2025 | 0 |
| December 2025 | 0 |
| January 2026 | 0 |
| February 2026 | 0 |
| March 2026 | 0 |
| April 2026 | 0 |
| May 2026 | 0 |